Skip to main
CLOV

CLOV Stock Forecast & Price Target

CLOV Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Clover Health Investments is poised to continue its strong performance in the coming years, thanks to its innovative software platform, Clover Assistant, which has shown its ability to effectively manage chronic diseases and contain medical costs. With strong retention rates and growth focused on markets where CA has been widely adopted, the company is well positioned to profitably absorb new members and continue improving its unit economics. While there may be some headwinds in 2027 due to a potential downgrade to a 3.5-star plan and flat CMS advance rates, management remains confident that their focus on technology and improving care outcomes will drive profitability. Overall, Clover Health Investments' unique approach to healthcare and strong financial performance make it a promising investment opportunity.

Bears say

Clover Health Investments is a healthcare technology company with a proprietary software platform aimed at managing chronic diseases. While the company achieved profitability in 2025, future headwinds such as a potential decrease in star ratings and flat payment rates in 2027 present risks to future profitability. Additionally, the Clover Assistant platform is facing competition in the marketplace and any regulatory changes to Medicare Advantage could negatively impact the company's financial outlook.

CLOV has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clover Health Investments (CLOV) Forecast

Analysts have given CLOV a Buy based on their latest research and market trends.

According to 3 analysts, CLOV has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clover Health Investments (CLOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.